BridgeBio Pharma Inc
(NASDAQ:BBIO)
$26.58
0[0.00%]
Last update: 4:00PM (Delayed 15-Minutes)
Get Real Time Here
$26.58
0[0.00%]
Open-Close-
Vol / Avg.36.000 / 3.060MMkt Cap4.319B
Day Range- - -52 Wk Range6.640 - 36.360

BridgeBio Pharma Stock (NASDAQ:BBIO), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$87.00

Lowest Price Target1

$19.00

Consensus Price Target1

$44.38

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
111100

Analyst Firms Making Recommendations1

  • Mizuho
  • JP Morgan
  • Goldman Sachs
  • Raymond James
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BridgeBio Pharma

All Ratings (39)

Upgrades (1)

Downgrades (1)

Initiations (3)

Q

What is the target price for BridgeBio Pharma (BBIO)?

A

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BridgeBio Pharma (BBIO)?

A

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

Q

Is the Analyst Rating BridgeBio Pharma (BBIO) correct?

A

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

BridgeBio Pharma Stock (NASDAQ:BBIO), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$87.00

Lowest Price Target1

$19.00

Consensus Price Target1

$44.38

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
111100

Analyst Firms Making Recommendations1

  • Mizuho
  • JP Morgan
  • Goldman Sachs
  • Raymond James
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BridgeBio Pharma

All Ratings (39)

Upgrades (1)

Downgrades (1)

Initiations (3)

Q

What is the target price for BridgeBio Pharma (BBIO)?

A

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BridgeBio Pharma (BBIO)?

A

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

Q

Is the Analyst Rating BridgeBio Pharma (BBIO) correct?

A

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

BridgeBio Pharma Stock (NASDAQ:BBIO), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$87.00

Lowest Price Target1

$19.00

Consensus Price Target1

$44.38

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
111100

Analyst Firms Making Recommendations1

  • Mizuho
  • JP Morgan
  • Goldman Sachs
  • Raymond James
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BridgeBio Pharma

All Ratings (39)

Upgrades (1)

Downgrades (1)

Initiations (3)

Q

What is the target price for BridgeBio Pharma (BBIO)?

A

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BridgeBio Pharma (BBIO)?

A

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

Q

Is the Analyst Rating BridgeBio Pharma (BBIO) correct?

A

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

BridgeBio Pharma Stock (NASDAQ:BBIO), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$87.00

Lowest Price Target1

$19.00

Consensus Price Target1

$44.38

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
111100

Analyst Firms Making Recommendations1

  • Mizuho
  • JP Morgan
  • Goldman Sachs
  • Raymond James
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BridgeBio Pharma

All Ratings (39)

Upgrades (1)

Downgrades (1)

Initiations (3)

Q

What is the target price for BridgeBio Pharma (BBIO)?

A

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BridgeBio Pharma (BBIO)?

A

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

Q

Is the Analyst Rating BridgeBio Pharma (BBIO) correct?

A

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

BridgeBio Pharma Stock (NASDAQ:BBIO), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$87.00

Lowest Price Target1

$19.00

Consensus Price Target1

$44.38

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
111100

Analyst Firms Making Recommendations1

  • Mizuho
  • JP Morgan
  • Goldman Sachs
  • Raymond James
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BridgeBio Pharma

All Ratings (39)

Upgrades (1)

Downgrades (1)

Initiations (3)

Q

What is the target price for BridgeBio Pharma (BBIO)?

A

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BridgeBio Pharma (BBIO)?

A

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

Q

Is the Analyst Rating BridgeBio Pharma (BBIO) correct?

A

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

BridgeBio Pharma Stock (NASDAQ:BBIO), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$87.00

Lowest Price Target1

$19.00

Consensus Price Target1

$44.38

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
111100

Analyst Firms Making Recommendations1

  • Mizuho
  • JP Morgan
  • Goldman Sachs
  • Raymond James
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BridgeBio Pharma

All Ratings (39)

Upgrades (1)

Downgrades (1)

Initiations (3)

Q

What is the target price for BridgeBio Pharma (BBIO)?

A

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BridgeBio Pharma (BBIO)?

A

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

Q

Is the Analyst Rating BridgeBio Pharma (BBIO) correct?

A

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

BridgeBio Pharma Stock (NASDAQ:BBIO), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$87.00

Lowest Price Target1

$19.00

Consensus Price Target1

$44.38

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
111100

Analyst Firms Making Recommendations1

  • Mizuho
  • JP Morgan
  • Goldman Sachs
  • Raymond James
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BridgeBio Pharma

All Ratings (39)

Upgrades (1)

Downgrades (1)

Initiations (3)

Q

What is the target price for BridgeBio Pharma (BBIO)?

A

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BridgeBio Pharma (BBIO)?

A

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

Q

Is the Analyst Rating BridgeBio Pharma (BBIO) correct?

A

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

BridgeBio Pharma Stock (NASDAQ:BBIO), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$87.00

Lowest Price Target1

$19.00

Consensus Price Target1

$44.38

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
111100

Analyst Firms Making Recommendations1

  • Mizuho
  • JP Morgan
  • Goldman Sachs
  • Raymond James
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BridgeBio Pharma

All Ratings (39)

Upgrades (1)

Downgrades (1)

Initiations (3)

Q

What is the target price for BridgeBio Pharma (BBIO)?

A

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BridgeBio Pharma (BBIO)?

A

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

Q

Is the Analyst Rating BridgeBio Pharma (BBIO) correct?

A

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

BridgeBio Pharma Stock (NASDAQ:BBIO), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$87.00

Lowest Price Target1

$19.00

Consensus Price Target1

$44.38

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
111100

Analyst Firms Making Recommendations1

  • Mizuho
  • JP Morgan
  • Goldman Sachs
  • Raymond James
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BridgeBio Pharma

All Ratings (39)

Upgrades (1)

Downgrades (1)

Initiations (3)

Q

What is the target price for BridgeBio Pharma (BBIO)?

A

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BridgeBio Pharma (BBIO)?

A

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

Q

Is the Analyst Rating BridgeBio Pharma (BBIO) correct?

A

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.